{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T02:26:51Z","timestamp":1769826411276,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jdiacomp.2023.108541","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T13:01:32Z","timestamp":1686402092000},"page":"108541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of SGLT2 inhibitors on the mechanisms of myocardial dysfunction in type 2 diabetes: A prospective non-randomized observational study in patients with type 2 diabetes mellitus without overt heart disease"],"prefix":"10.1016","volume":"37","author":[{"given":"Petra","family":"Grubi\u0107 Rotkvi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"\u0106elap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerija","family":"Brali\u0107 Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juraj","family":"Jug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Snagi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Huljev \u0160ipo\u0161","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Cigrovski Berkovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2023.108541_bb0005","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.pharmthera.2014.01.003","article-title":"Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways","volume":"142","author":"Huynh","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0010","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1530\/EJE-17-0724","article-title":"Mechanisms in endocrinology: diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review","volume":"178","author":"Levelt","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","article-title":"Role of diabetes in congestive heart failure: the Framingham study","volume":"34","author":"Kannel","year":"1974","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0020","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0025","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013389","article-title":"SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects","volume":"8","author":"Lam","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0030","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0035","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cardfail.2022.02.010","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure","volume":"28","author":"Writing Committee Members; ACC\/AHA Joint Committee Members","year":"2022","journal-title":"J Card Fail"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0040","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.diabres.2013.07.004","article-title":"The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: data from the SHORTWAVE study","volume":"101","author":"Faden","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0045","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/1741826711417759","article-title":"DYDA Investigators. Analysis of midwall shortening reveals high prevalence of left ventricular myocardial dysfunction in patients with diabetes mellitus: the DYDA study","volume":"19","author":"Cioffi","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0050","first-page":"101","article-title":"Potential mechanisms responsible for cardioprotectiveeffects of sodium\u2013glucose co-transporter 2 inhibitors","volume":"17","author":"Lahnwong","year":"2018","journal-title":"CardiovascDiabetol."},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0055","doi-asserted-by":"crossref","DOI":"10.1210\/er.2010-0029","article-title":"Role of sodium-glucose cotransporters 2 (SGLT2) inhibitors in the treatment of type 2 diabetes","volume":"32","author":"Abdul-Ghani","year":"2011","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0060","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4239\/wjd.v11.i7.269","article-title":"Sodium-glucose cotransporter 2 inhibitors\u2019 mechanisms of action in heart failure","volume":"11","author":"Grubi\u0107 Rotkvi\u0107","year":"2020","journal-title":"World J Diabetes"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0065","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0070","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMra0800239","article-title":"Biomarkers in heart failure","volume":"358","author":"Braunwald","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0075","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12933-021-01221-w","article-title":"Performance of the recommended ESC\/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus","volume":"20","author":"Prausm\u00fcller","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0080","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s10741-019-09849-3","article-title":"Minireview: are SGLT2 inhibitors heart savers in diabetes?","volume":"25","author":"Grubi\u0107 Rotkvi\u0107","year":"2020","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0085","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.peptides.2003.07.030","article-title":"Atrial natriuretic peptide and endothelin-3 target renal sodium-glucose cotransporter","volume":"24","author":"Majowicz","year":"2003","journal-title":"Peptides"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0090","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12933-022-01618-1","article-title":"Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial","volume":"21","author":"Nesti","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0095","doi-asserted-by":"crossref","first-page":"86A","DOI":"10.1016\/0735-1097(93)90468-G","article-title":"Atrial natriuretic peptide in heart failure","volume":"22","author":"Brandt","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0100","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0105","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/jcm8060779","article-title":"Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors","volume":"8","author":"Eickhoff","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ahj.2020.07.011","article-title":"Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: a double-blinded, randomized, and placebo-controlled trial","volume":"228","author":"Jensen","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0115","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.jacc.2021.07.046","article-title":"Prognostic importance of NT-proBNP and effect of empagliflozin in the EMPEROR-reduced trial","volume":"78","author":"Januzzi","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0120","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00018-022-04289-z","article-title":"Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin","volume":"79","author":"La Grotta","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes","volume":"85","author":"Garvey","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0130","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0135","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13098-018-0395-5","article-title":"Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance","volume":"18","author":"Hattori","year":"2018","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0140","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12933-021-01385-5","article-title":"Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence","volume":"20","author":"Natali","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0145","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7570\/jomes.2019.28.4.254","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase 4 inhibitors on cardiovascular function in patients with type 2 diabetes mellitus and coronary artery disease","volume":"28","author":"Lee","year":"2019","journal-title":"J Obes Metab Syndr"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0150","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1253\/circj.CJ-20-0341","article-title":"Dapagliflozin influences ventricular hemodynamics and exercise-induced pulmonary hypertension in type 2 diabetes patients - a randomized controlled trial","volume":"84","author":"Kayano","year":"2020","journal-title":"Circ J"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0155","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.3390\/ijms22115437","article-title":"Low-dose empagliflozin improves systolic heart function after myocardial infarction in rats: regulation of MMP9, NHE1, and SERCA2a","volume":"22","author":"Goerg","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0160","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"26","author":"Lin","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0165","doi-asserted-by":"crossref","first-page":"H310","DOI":"10.1152\/ajpheart.01218.2005","article-title":"Increased cardiac output and microvascular blood flow during mild hemoconcentration in hamster window model","volume":"291","author":"Martini","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0170","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/metabo11020087","article-title":"The effects of SGLT2 inhibitors on lipid metabolism","volume":"11","author":"Szekeres","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105319","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: a systematic review and meta-analysis of randomized controlled trials","volume":"163","author":"Simental-Mend\u00eda","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0180","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/hrt.2006.090845","article-title":"Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independentely of B-type natriuretic peptide levels","volume":"93","author":"Kittleson","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.jdiacomp.2023.108541_bb0185","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1161\/01.CIR.0000066420.36123.35","article-title":"Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology","volume":"107","author":"Hare","year":"2003","journal-title":"Circulation"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872723001393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872723001393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:18:08Z","timestamp":1761005888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872723001393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1056872723001393"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108541","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of SGLT2 inhibitors on the mechanisms of myocardial dysfunction in type 2 diabetes: A prospective non-randomized observational study in patients with type 2 diabetes mellitus without overt heart disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108541","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108541"}}